Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel iron chelators described by BTG

Oct. 8, 2009

LY-2189265 does not affect serum lipase and amylase levels in type 2 diabetes

Oct. 8, 2009

DSP-8658 shows favorable antidiabetic activity in mouse models of obesity and diabetes

Oct. 8, 2009

Vantia Therapeutics' VA-111913 enters phase II proof-of-concept trial for dysmenorrhea

Oct. 7, 2009

Onglyza receives marketing authorization in Europe for type 2 diabetes

Oct. 7, 2009

Novartis and Xenon Pharmaceuticals claim SCD inhibitors for the treatment of dyslipidemia

Oct. 7, 2009

Novel PPARgamma agonist for the treatment of diabetes described by Adamed

Oct. 6, 2009

Amicus Therapeutics reports results of phase II Plicera study for Gaucher disease

Oct. 6, 2009

FDA approves new indication of Bayer's Mirena for heavy menstrual bleeding

Oct. 6, 2009

ACE-031 increases lean body mass and muscle volume in healthy postmenopausal women

Oct. 6, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...